Today at ASCO, our collaborators from the University of California, Irvine presented groundbreaking new data demonstrating the role of certain genomic alterations, known as MET exon 14 (METex14), as drivers of growth of non-small cell lung cancer (NSCLC). These findings identify a unique subset of patients likely to benefit from certain MET inhibitor targeted therapies. Strikingly, the analysis showed that the METex14 alterations occurred in more than 3% of non-small cell lung cancers and identified NSCLC patients who derived meaningful clinical benefit from treatment with MET inhibitor targeted therapies.
These data show the significance and power of precision medicine. METex14 alterations, which can typically only be identified using a comprehensive genomic profile like FoundationOne®, do not occur with other known drivers of NSCLC, thus providing a unique opportunity to treat these patients with targeted therapies that would otherwise not have been considered. Identification of this patient population by comprehensive genomic profiling with FoundationOne is an important step towards making targeted therapy available for a wider range of patients with NSCLC. Further, the addition of METex14 alterations to the growing list of oncogenic drivers in NSCLC supports the need for broad reimbursement coverage of comprehensive genomic profiling to allow a full understanding of the genomic drivers of a patient’s tumor and the matched targeted therapeutic approaches to drive improved outcomes for patients.
The data were presented in an oral presentation titled, “Comprehensive genomic profiling of advanced cancers to identify MET exon 14 alterations that confer sensitivity to MET inhibitors” (abstract #11007), by Ignatius Ou, M.D., Ph.D., health science associate clinical professor, University of California, Irvine.
For more information on the data, see our press release.